Clinical Trial

SILibinin in NSCLC and BC Patients With Single Brain METastasis (SILMET)

Study acronym: SILMET
Recruiting
View on ClinicalTrials.gov →
Record status
This record was last updated December 15, 2023 (before its estimated September 1, 2025 completion). Its status may not reflect the trial's current state.
Summary
This study aims to evaluate the efficacy of silibinin in preventing recurrence in the brain after complete resection of a brain metastasis (BM) from non-small-cell lung cancer (NSCLC) or breast cancer (BC).
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2023-01-09.
Trial Details
NCT Number NCT05689619
Lead Sponsor A.O.U. Città della Salute e della Scienza
Conditions Brain Metastases, Adult, Non Small Cell Lung Cancer, Breast Cancer
Enrollment 70 participants
Start Date 2023-09-01
Primary Completion 2025-09-01 (estimated)
Study Completion 2027-09-01 (estimated)
Updated on ClinicalTrials.gov 2023-12-15